Skip to content

Myobloc (Botulinum Toxin Type B) for Muscle Spasms and Dystonia

Published: July 26, 2026Updated: July 26, 2026

Myobloc is an injectable botulinum toxin that temporarily reduces excessive muscle activity. It is used to treat cervical dystonia, adult spasticity, and upper-limb spasticity in children age 2 and older.

Quick summary

Myobloc can help reduce troublesome muscle tightness or spasms when other treatments are not enough. It must be given by a trained healthcare professional using a personalized dose and injection plan.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

RxNorm
284792
Generic
Myobloc
Class
brand-name
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy